Shimadzu Corporation aims at sales of 5,7 billion Yen for molecular diagnostics by 2017

Major targets are cell analysis (2 billion) and molecular diagnostics (3,3 billion)

Nikkei Biotech, March 27, 2014

Most popular posts: